HomeActive Pharmaceutical Ingredients

Active Pharmaceutical Ingredients

Catalog No. Product Name Information
A2739 Anti-158P1D7 Anti-158P1D7 is a monoclonal anti-158P1D7 antibody used in the production of antibody drug conjugates (adc) that bind to 158P1D7 proteins. MW: 146.0 KD.
A2740 Anti-Dysadherin Anti-Dysadherin is a monoclonal antibody against dysadherin with anti-metastasis activity. MW: 147.56 KD.
A2741 Anti-TMEFF1 / Tomoregulin-1 Anti-TMEFF1 / Tomoregulin-1 is a monoclonal antibody against TMEFF1 (a transmembrane protein with EGF-like and two Follistatin-like domains, Tomoregulin 1), a type I transmembrane glycoprotein. MW: 146.08 KD.
A2742 Anti-c-RET Anti-c-RET is a monoclonal antibody against the receptor tyrosine kinase Ret (c-Ret) expressed in cells of neuroblastoma and substantia nigra, a responsive locus of Parkinson's disease. MW: 146.74 KD.
A2745 Anti-Integrin a11 / ITAG11 Anti-Integrin a11 / ITAG11 is a monoclonal antibody against Integrin alpha 11 (ITGA11), a transmembrane glycoprotein expressed in adult cardiac and uterine smooth muscle and developing myocytes. MW: 145.7 KD.
A2749 Anti-DSG3 Anti-DSG3 is an anti-desmoglein 3 (Dsg3) monoclonal antibody that depletes desmosomes of Dsg3 and has the potential to be used in research on Pemphigus vulgaris (PV). MW: 146.54 KD.
A2752 Anti-MUSK Anti-MUSK is a monoclonal IgG antibody against muscle-specific kinase (MuSK) with the potential to treat Myasthenia gravis. MW: 145.24 KD.
A2756 Anti-SCN11a / Nav1.9 Anti-SCN11a / Nav1.9 is a monoclonal anti-Nav1.9 (SCN11A) antibody used in antigen-specific immunodetection in biological samples. MW: 143.94 KD.
A2757 Anti-TLR7 Anti-TLR7 is a monoclonal antibody against Toll-like receptor 7 (TLR7) with the potential to treat autoimmune disease. MW: 145.04 KD.
A2761 Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7) Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7) is a fully human monoclonal immunoglobulin G2 antibody that targets the alpha4beta7 integrin and prevents interaction with MADCAM-1. It has the potential to be used in research on inflammatory bowel disease (IBD). MW: 143.8 kD.
A2773 Anti-MSPR / RON / CD136 Anti-MSPR / RON / CD136 is a monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), and can be used in cancer research. MW: 139.86 KD.
A2776 Batoclimab (Anti-FcRn (FCGRT & B2M)) Batoclimab (anti-FcRn (FCGRT & B2M)) is a human monoclonal antibody directed against the neonatal crystallizable fragment receptor (FcRn) with potential immunomodulating activity. It has the potential to be used in research on autoimmune diseases mediated by pathogenic IgG antibodies. MW: 143.76 kD.
A2782 Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1-kappa, anti-(homo sapiens CD274 (programmed death ligand 1, PDL1, pd-l1, B7 homolog 1, B7H1)), monoclonal antibody. MW: 144.6 kD.
A3039 Tislelizumab (Anti-PDCD1 / PD-1 / CD279) Tislelizumab (Anti-PDCD1 / PD-1 / CD279) is a monoclonal antibody targeting programmed cell death protein 1 (anti-PD-1). It can be used for the research of advanced squamous non-small-cell lung cancer. MW :144.46 KD
A3047 Anti-PRLR / Prolactin Receptor Anti-PRLR / Prolactin Receptor is a potent monoclonal antibody, targeting prolactin (PRL) receptor. It is considered a good candidate for further development in endometriosis or other PRL-mediated disease conditions. MW :143.8 KD
A2792 Anti-ABCB5 Anti-ABCB5 is a monoclonal antibody (mAb) against ABCB5 (ATP-binding cassette transporter, sub-family B (MDR/TAP), member 5) with the potential to be used in research on melanoma. MW: 147.74 KD.
A2793 Anti-CD151 Anti-CD151 is an anti-CD151 monoclonal antibody (mAb) with potential anti-metastatic and anti-tumor activity activity. MW: 146.76 KD.
A2794 Anti-EMMPRIN / CD147 Anti-EMMPRIN / CD147 is a monoclonal antibody against extracellular matrix metalloproteinase inducer (EMMPRIN; CD147) with potential anti-proliferative activity. MW: 145.42 KD.
A2797 Anti-IL-25 Anti-IL-25 is a humanised monoclonal antibody against Interleukin-25 (IL-25) with the potential to treat airway hyperresponsiveness (AHR). MW: 146.02 KD.
D4058 IMGN779 IMGN779 is an antibody-drug conjugate (ADC) targeting CD33. It exhibits promising therapeutic approaches in acute myeloid leukemia (AML). MW :146.48 KD.